SAB Biotherapeutics (SABS) FCF Margin (2021 - 2024)
SAB Biotherapeutics' (SABS) quarterly FCF Margin came in at 8358.96% in Q4 2024, down 392811.0% YoY from N/an in Q1 2024, and down 183.07% on a QoQ basis from 2952.95% in Q2 2024.
Powered by 
Analysis
SAB Biotherapeutics (SABS) FCF Margin (2021 - 2024) Analysis & Trends
SAB Biotherapeutics (SABS) has 4 years of FCF Margin data on file, last reported at 8358.96% in Q4 2024.
- Quarterly FCF Margin fell 392811.0% year-over-year to 8358.96% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 2618.65% (down 148794.0% YoY) and the FY2024 annual result came in at 2618.65%, down 148794.0% from the prior year.
- FCF Margin fell to 8358.96% in Q4 2024, from 2952.95% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 44.68% in Q1 2021 to a low of 8358.96% in Q4 2024.
- A 4-year average of 1592.5% and a median of 222.78% in 2022 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2023 — FCF Margin slumped 567563 bps — and 2024, when it soared 280238 bps.
- Tracing SABS's FCF Margin over 4 years: stood at 65.47% in 2021, then declined by 18 bps to 77.41% in 2022, then slumped by 5624 bps to 4430.85% in 2023, then plunged by 89 bps to 8358.96% in 2024.
- The last three FCF Margin figures came in at 8358.96% (Q4 2024), 2952.95% (Q2 2024), and 1151.74% (Q1 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | SAB Biotherapeutics | 296.68 Mn | 296.68 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -8,358.96% |
| Jun 30, 2024 | -2,952.95% |
| Mar 31, 2024 | -1,151.74% |
| Dec 31, 2023 | -4,430.85% |
| Sep 30, 2023 | -414.49% |
| Jun 30, 2023 | -5,755.33% |
| Mar 31, 2023 | -279.99% |
| Dec 31, 2022 | -77.41% |
| Sep 30, 2022 | -222.78% |
| Jun 30, 2022 | -79.69% |
| Mar 31, 2022 | -92.31% |
| Dec 31, 2021 | -65.47% |
| Sep 30, 2021 | 3.88% |
| Jun 30, 2021 | -54.09% |
| Mar 31, 2021 | 44.68% |